Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 2, 2010, Pages 304-310

  Choi, Chel Hun ^a   Song, Sang Yong ^a   Kang, Heeseok ^a   Lee, Yoo Young ^a   Kim, Chul Jung ^a   Lee, Jeong Won ^a   Kim, Tae Joong ^a   Kim, Byoung Gie ^a   Lee, Je Ho ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Bulky cervical carcinoma; Immunohistochemistry; P STAT3

Indexed keywords

CISPLATIN; MITOMYCIN C; PARAFFIN; STAT3 PROTEIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; TREATMENT RESPONSE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; PHOSPHORYLATION; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; UTERINE CERVICAL NEOPLASMS;

EID: 77950219390     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2009.01131.x     Document Type: Article

References (37)

1. Korean Society of Obstetrics and Gynecology CoGO. Annual report of gynecologic cancer registry program in Korea for 2004 (2004.1.1-2004.12.31). Korean J Obstet Gynecol 2007 50 : 28 78.
2. Lee YK, Han SS, Kim JW, Park NH, Song SY, Kang SB. Value of pelvic examination and imaging modality for the evaluation of tumor size in cervical cancer. J Gynecologic Oncology 2008 19 : 108 112.
3. Thomas GM. Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy. N Engl J Med 1999 340 : 1198 1200.
4. Pignata S, Silvestro G, Ferrari E et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol 1999 17 : 756 760.
5. Serur E, Mathews RP, Gates J, Levine P, Maiman M, Remy JC. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix. Gynecol Oncol 1997 65 : 348 356.
6. Darnell JE, Jr. STATs and gene regulation. Science 1997 277 : 1630 1635.
7. Turkson J, Jove R. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene 2000 19 : 6613 6626.
8. Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an oncogene. Cell 1999 98 : 295 303.
9. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002 8 : 945 954.
10. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000 19 : 2474 2488.
11. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 2000 79 : 67 73.
12. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004 4 : 97 105.
13. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002 21 : 7611 7618.
14. Dalton WS, Jove R. Drug resistance in multiple myeloma: Approaches to circumvention. Semin Oncol 1999 26 : 23 27.
15. Chen CL, Hsieh FC, Lieblein JC et al. Stat3 activation in human endometrial and cervical cancers. Br J Cancer 2007 96 : 591 599.
16. Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol 2007 104 : 64 69.
17. Choi CH, Song SY, Choi JJ et al. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. BMC Cancer 2008 8 : 295.
18. Buda A, Fossati R, Colombo N et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 2005 23 : 4137 4145.
19. Ribeiro U Jr., Finkelstein SD, Safatle-Ribeiro AV et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998 83 : 7 18.
20. Yang SF, Yuan SS, Yeh YT et al. The role of p-STAT3 (ser727) revealed by its association with Ki-67 in cervical intraepithelial neoplasia. Gynecol Oncol 2005 98 : 446 452.
21. Mora LB, Buettner R, Seigne J et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002 62 : 6659 6666.
22. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: A study of incidence and its association with pathological features and clinical outcome. J Urol 2002 168 : 762 765.
23. Masuda M, Suzui M, Yasumatu R et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002 62 : 3351 3355.
24. Khoury JD, Medeiros LJ, Rassidakis GZ et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003 9 : 3692 3699.
25. Gong W, Wang L, Yao JC et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005 11 : 1386 1393.
26. Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K, Sekine I. Expression of p-STAT3 in human gastric carcinoma: Significant correlation in tumour invasion and prognosis. Int J Oncol 2007 30 : 437 442.
27. Kusaba T, Nakayama T, Yamazumi K et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 2006 15 : 1445 1451.
28. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003 9 : 594 600.
29. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006 65 : 1181 1188.
30. Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 2003 89 : 344 349.
31. Nakajima K, Yamanaka Y, Nakae K et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996 15 : 3651 3658.
32. Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999 10 : 105 115.
33. Niu G, Bowman T, Huang M et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002 21 : 7001 7010.
34. Kanda N, Seno H, Konda Y et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004 23 : 4921 4929.
35. Chapman RS, Lourenco PC, Tonner E et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999 13 : 2604 2616.
36. Bromberg J, Darnell JE, Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000 19 : 2468 2473.
37. Levy DE, Darnell JE Jr. Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002 3 : 651 662.